Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
The U.S. Food and Drug Administration has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels.
NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
European Commission and the World Health Organization (WHO) are co-hosting the world's first Global Vaccination Summit in Brussels.
The aim is to accelerate global action to stop the spread of vaccine-preventable diseases, and advocate against the spread of vaccine misinformation worldwide.
Allergy to peanut, which is often severe, is one of the most common food allergies in the United States.
Although previous studies have shown that peanut oral immunotherapy (OIT) — ingesting small, controlled amounts of peanut protein - can desensitize adults and children and prevent life-threatening allergic reactions, the optimal duration and dose is unknown.
EMA’s Executive Director has asked the human medicines committee (CHMP) to provide guidance for avoiding the presence of nitrosamine impurities in human medicines containing chemically synthesised active substances.
Pregnant women who are exposed to higher air pollution levels during their second pregnancy, compared to their first one, may be at greater risk of preterm birth, according to researchers at the National Institutes of Health.
Their study appears in the International Journal of Environmental Research and Public Health.
The Pan American Health Organization (PAHO) is requesting an initial USD 3.5 million from donors to cover short-term health care and other needs for the population in the Bahamas affected by Hurricane Dorian.
The devastating category 5 storm made landfall exactly one week ago in northwest Bahamas, and severely affected the health sector, with significant destruction of equipment and medical supplies and electrical and water supplies in Abaco and Grand Bahama. Some 73,000 persons were affected by the storm, and there are hundreds of people in shelters in the disaster zone. While 43 deaths have been officially reported thus far, mass casualty numbers are expected to rise significantly as more areas become accessible and search and rescue operations continue.
Dr. Ciro Ugarte, PAHO’s Director of Health Emergencies, said, “Our priority concerns are to restore access to essential health services and continued medical care delivery, to ensure water quality in affected communities and health facilities, and to restore proper hygiene and sanitation.” He said adequate waste management and control of disease-causing vectors such as mosquitoes is key, along with increasing epidemiological surveillance to support early detection and timely management of disease outbreaks.
The 3.5 million being requested by PAHO is a preliminary estimate to cover short- term healthcare, water and sanitation, epidemiological surveillance and vector-control needs in the Bahamian Islands most affected by Hurricane Dorian for the next six months, Dr. Ugarte said, adding that needs will likely increase as damage assessments are completed.
PAHO/WHO activated its emergency teams for surge capacity and had pre-deployed Rapid Response Team experts to the Bahamas before Hurricane Dorian struck to support health authorities and humanitarian response as needs were identified. So far, 14 PAHO experts are in the disaster zone to provide surge capacity in logistics, civil and military coordination, information management, epidemiological surveillance, communications, and coordination.
Dr. Ugarte said PAHO is acting quickly to support the Bahamas Ministry of Health in the response, setting up an Incident Management system and co-leading the health cluster with the national health authorities to coordinate health and humanitarian support to the affected population.
The funding requests includes USD 1.3 million to restore healthcare delivery in affected areas, USD 500,000 for surveillance to detect and manage disease outbreaks, USD 800,000 for safe access to water, emergency sanitation and control of disease vectors, and well as USD 671,000 to coordinate humanitarian assistance and manage information to address the most urgent humanitarian needs.
Indoco Remedies announced that the Inspection Action Group (IAG) of the United Kingdom has confirmed that the GMP status for its Goa Plant I has been fully re-instated by UK regulator, The Medicines and Healthcare Products Regulatory Agency of the United Kingdom (UK-MHRA). This is an outcome of the full GMP inspection conducted by the MHRAfrom May 21 - 23, 2019.
Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China.
Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China.
India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This was announced by the Department of Biotechnology, Ministry of Science & Technology in New Delhi.
India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This was announced by the Department of Biotechnology, Ministry of Science & Technology in New Delhi. This expands the global partnership working to address challenges and improve coordination and collaboration in global AMR R&D to 16 countries, the European Commission, two philanthropic foundations and four international organisations (as observers).
To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings.
To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings. Brown University, Providence, Rhode Island, will partner with Hebrew Senior Life, a Harvard Medical School Affiliate, Roslindale, Massachusetts, to manage the Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory with funding from NIA that is expected to total $53.4 million over five years. IMPACT Collaboratory researchers will team with scientists at other universities with health care and long-term care systems to guide research to develop and test novel ways to care for people with AD/ADRD.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
